GAITHERSBURG, Md., Nov. 18, 2022 /PRNewswire/ -- Novavax, Inc. (NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

It can take a long time to create a new vaccine and at the same time, there have been many evolutions and new strains of the ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. American adults who haven't yet gotten vaccinated against COVID-19 should consider a new option ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novavax ( (NVAX)) has issued an update.

How the United States' potential fourth vaccine stacks up against existing ones. Maryland-based biotech company Novavax said Monday that its COVID-19 vaccine was shown to be highly effective in ...

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...